Impact of Behavior Change on GLP-1 Weight Loss

This technical report presents an analysis of the effectiveness of GLP-1 medications for weight loss when combined with behavior change support through the Omada for Prevention program. The report outlines the significant increase in GLP-1 prescriptions for weight loss, noting a 2000% rise since 2019, and highlights the clinical trial results of Wegovy® and Saxenda®. The analysis conducted by Omada utilized pharmacy claims data to evaluate the weight loss outcomes of members engaged in the Omada program while using GLP-1 medications. It details the methodology, including the retrospective propensity-score matched analysis, and discusses the relationship between program engagement and weight loss success. The findings indicate that higher engagement in the Omada program correlates with greater weight loss among GLP-1 users. The report concludes with considerations for future research on the integration of behavior change programs with medication for obesity treatment, addressing challenges such as medication adherence and cost implications for patients and health plans.